Galectin Therapeutics Inc (GALT)
NASDAQ:GALT
Want to see GALT full AI Analyst Report?
GALT Stock Chart & Stats
$5.71
-$0.06(-5.00%)
At close: 4:00 PM EST
$5.71
-$0.06(-5.00%)
Day’s Range― - ―
52-Week Range$1.21 - $7.13
Previous CloseN/A
Volume135.57K
Average Volume (3M)341.94K
Market Cap
$150.74M
Enterprise Value$262.81M
Total Cash (Recent Filing)$17.72M
Total Debt (Recent Filing)$133.74M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding65,827,446
10 Day Avg. Volume287,288
30 Day Avg. Volume341,945
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)-2.11
Price to Sales (P/S)0.00
P/FCF Ratio-11.13
Enterprise Value/Market Cap1.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-11.21
Forecast
1Y Price Target
$11.00Price Target Upside92.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker-driven Patient SelectionImprovements in fibrosis‑related biomarkers and liver function measures support that belapectin targets fibrosis pathways and could enable more effective patient selection in future trials.
Clinical EfficacyBelapectin reduced the incidence of new esophageal varices versus placebo, indicating a potentially unique clinical benefit for patients at risk of varices.
Regulatory Engagement And VisibilityAnalyst expects constructive FDA feedback and the drug's recent acceptance for an oral presentation at a major liver conference to strengthen prospects for a clear Phase 3 plan and renewed investor interest.
Bears Say
Clinical Development Funding VulnerabilityIf clinical development requires additional resources, limited independent liquidity may force program delays or reductions in scope.
Financing And Dilution RiskLimited internal funding capacity increases the likelihood of pursuing external financing on unfavorable terms, which could dilute existing shareholders.
Funding Concentration RiskLiquidity reliance on a credit line from the company chair creates concentration risk and could leave the program vulnerable if that support is withdrawn.
Galectin Therapeutics News
GALT FAQ
What was Galectin Therapeutics Inc’s price range in the past 12 months?
Galectin Therapeutics Inc lowest stock price was $1.21 and its highest was $7.13 in the past 12 months.
What is Galectin Therapeutics Inc’s market cap?
Galectin Therapeutics Inc’s market cap is $150.74M.
When is Galectin Therapeutics Inc’s upcoming earnings report date?
Galectin Therapeutics Inc’s upcoming earnings report date is May 18, 2026 which is in 11 days.
How were Galectin Therapeutics Inc’s earnings last quarter?
Galectin Therapeutics Inc released its earnings results on Mar 31, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.06 by -$0.02.
Is Galectin Therapeutics Inc overvalued?
According to Wall Street analysts Galectin Therapeutics Inc’s price is currently Undervalued.
Does Galectin Therapeutics Inc pay dividends?
Galectin Therapeutics Inc does not currently pay dividends.
What is Galectin Therapeutics Inc’s EPS estimate?
Galectin Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galectin Therapeutics Inc have?
Galectin Therapeutics Inc has 65,827,446 shares outstanding.
What happened to Galectin Therapeutics Inc’s price movement after its last earnings report?
Galectin Therapeutics Inc reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.06. Following the earnings report the stock price went up 8.56%.
Which hedge fund is a major shareholder of Galectin Therapeutics Inc?
Currently, no hedge funds are holding shares in GALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Galectin Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (92.64% Upside)
$11.00 (92.64% Upside)
Insider Transactions
Bought Shares
Worth $810.0 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.59%
12-Months-Change
Fundamentals
Return on Equity
25.65%
Trailing 12-Months
Asset Growth
11.64%
Trailing 12-Months
Company Description
Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
GALT Stock 12 Month Forecast
Average Price Target
$11.00
▲(92.64% Upside)
Technical Analysis
Omeros
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Jade Biosciences
―
Tenaya Therapeutics
―
Ownership Overview
27.64% Insiders
3.82% Mutual Funds
2.22% Other Institutional Investors
63.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---